Otsuka (OTSKY) Expected to Post Earnings on Thursday

Otsuka (OTCMKTS:OTSKY) is expected to be issuing its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $0.5060 per share and revenue of $3.9475 billion for the quarter.

Otsuka (OTCMKTS:OTSKY) last posted its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.16. The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. On average, analysts expect Otsuka to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Otsuka Stock Performance

Shares of OTCMKTS OTSKY opened at $34.80 on Wednesday. The firm’s 50-day moving average price is $34.23 and its 200-day moving average price is $33.43. Otsuka has a 52-week low of $23.50 and a 52-week high of $37.52. The company has a market cap of $37.38 billion and a PE ratio of 14.68. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Otsuka presently has an average rating of “Hold”.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.